Skip to content

Prevention of Syncope (fainting) Trial 11

Fainting

About 20% of adults faint regularly. No treatments are proven useful in executed clinical trials. This is a study to test the theory that Ondansetron reduces the time to a recurrence of faint in a TILT test. In this study half the patients will receive Ondansetron the night before and the morning of the study day ( TILT Table test) the other half will receive a Placebo. you need to fill in two surveys. No follow-up needed after the study day.

null

Conditions de participation

  • Sexe:

    Male, Female, Intersex

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:
1. ≥1 faints in the year preceding enrolment
2. Vasovagal Syncope
3. Age ≥ 18 years
Exclusion Criteria:
(1) other causes of syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or hypersensitive carotid sinus syndrome
(2) an inability to give informed consent
(3) important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia
(4) hypertrophic cardiomyopathy
(5) a permanent pacemaker
(6) a seizure disorder
(7) hypertension defined as >160/90 mm Hg
(8) pregnancy
(9) lactating women
(10) glaucoma
(11) medications with known effects on BP
(12) Known hypersensitivity to ondansetron and related medications
(13) other factors which, in the investigator’s opinion, would prevent the subject from completing the protocol.

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: REB23-0198